Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025

Monte Rosa Therapeutics, Inc.

Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.
Cash and marketable securities $207.6M at June 30, expected to fund operations into 2025.
CFO Ajim Tamboli resigned; no replacement announced yet.
Initial Phase 1/2 data for MRT-2359 expected H2 2023; IND for MRT-6160 expected H1 2024.
FDA Orphan Drug Designation for MRT-2359 for small cell lung cancer received.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Monte Rosa Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $35.2 million.

Period: the quarter ended June 30, 2023
Net income: $35.2 million
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $35.2 million

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.